Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,068 across all filing types
Latest filing 2023-11-16 Interim / Quarterly Rep…
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport för perioden 1 januari – 30 september 2023' (Interim report for the period 1 January – 30 September 2023) for Vivesto AB. It contains comprehensive financial statements, including income statements, cash flow analysis, and management commentary on business performance for the third quarter and the nine-month period. It is a substantive financial report, not an announcement or a certification, and therefore fits the definition of an Interim/Quarterly Report. 9M 2023
2023-11-16 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'Interim report for the period January 1, 2023 – September 30, 2023'. It contains comprehensive financial statements, including consolidated income statements, cash flow analysis, and detailed management commentary on business operations and strategic direction. It is not an announcement of a report, but the report itself, and it covers a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2023
2023-11-16 English
Vivesto focuses its project portfolio and introduces cost-saving measures
Regulatory Filings Classification · 98% confidence The document is a press release dated October 25, 2023, announcing strategic portfolio focus, cost-saving measures, discontinuation of certain projects (XR-18 platform, Uppsala labs), and securing financing until the end of 2026. It details operational changes and future development plans for Cantrixil and Paccal Vet. This type of announcement, detailing significant business strategy shifts and operational changes, is typically classified as an Earnings Release (ER) if it accompanies financial results, or a general Regulatory Filing (RNS) if it's purely operational/strategic news. Since it is a formal announcement of strategic business decisions and cost restructuring, and it is explicitly labeled as a 'Press Release', it fits best under the general 'Regulatory Filings' (RNS) category as it is not a full financial report (10-K, IR), a specific management discussion (MDA), or a formal earnings release (ER) which usually contains summarized figures. However, given the content is a major operational update, RNS is the most appropriate fallback for significant, non-standard announcements. The document length (5027 chars) is substantial enough to be the primary announcement, not just a link announcement (RPA).
2023-10-25 English
Vivesto fokuserar projektportföljen och inför kostnadsbesparande åtgärder
Regulatory Filings Classification · 98% confidence The document is a press release dated October 25, 2023, announcing strategic focus changes, cost-saving measures, and the cessation of certain R&D activities. It includes a concluding statement: "Denna information är sådan information som Vivesto AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning" (This information is information that Vivesto AB is obliged to disclose pursuant to the EU's Market Abuse Regulation). This strongly indicates a mandatory regulatory disclosure. Since it is not a full annual report (10-K), a quarterly report (IR), an earnings release (ER), or a specific shareholder vote result (DVA), and it is a general announcement of material company information required by regulation, the most appropriate general regulatory filing category is RNS (Regulatory Filings). The document length is relatively short (4770 chars) and it announces information rather than being the full detailed report itself, supporting a classification as a general regulatory announcement.
2023-10-25 Swedish
Delisting of Vivesto’s shares from Frankfurt Stock Exchange effective as of 15 September 2023
Delisting Announcement Classification · 100% confidence The document explicitly announces the 'Delisting of Vivesto's shares from Frankfurt Stock Exchange effective as of 15 September 2023.' This directly corresponds to the definition of a Delisting Announcement (Code: DLST). The document is short and serves as an official notice regarding the removal of stock listing.
2023-09-15 English
Avnotering av Vivestos aktier från Frankfurt Stock Exchange per den 15 september 2023
Delisting Announcement Classification · 98% confidence The document is a short announcement (2770 characters) in Swedish titled "Avnotering av Vivestos aktier från Frankfurt Stock Exchange per den 15 september 2023" (Delisting of Vivesto's shares from Frankfurt Stock Exchange as of September 15, 2023). It explicitly states that the Frankfurt Stock Exchange (FSE) has decided to delist the shares due to non-compliance with listing rules. The document concludes with a section titled "Bifogade filer" (Attached files) which links to the full announcement PDF. According to Rule #2 (The "MENU VS MEAL" Rule), a short document announcing the publication of a filing or decision, rather than being the comprehensive report itself, should be classified as a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Since this is a specific regulatory action announcement (delisting), it fits best under the general Regulatory Filings category (RNS) as it is an official notice of a corporate action/event, or potentially RPA if interpreted as announcing the publication of the formal notice. Given the content is a definitive announcement of a corporate action (delisting), RNS is a strong fit for general regulatory news, but RPA is also plausible as it announces the final decision/publication. However, since 'Delisting Announcement' (DLST) is a specific category, I must check if this announcement qualifies. DLST is defined as 'Official notice that the company's stock will be removed from an exchange.' This document is precisely that official notice. Therefore, DLST is the most specific and accurate classification.
2023-09-15 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.